Compare
Vera Therapeutics, Inc. vs Kura Oncology, Inc. vs Schrodinger, Inc. vs Summit Therapeutics Inc.
| Latest fiscal year | Vera Therapeutics, Inc. VERA | Kura Oncology, Inc. KURA | Schrodinger, Inc. SDGR | Summit Therapeutics Inc. SMMT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $67.48M | $255.87M | n/a |
| Revenue growth (YoY) | n/a | +25.2% | +23.3% | n/a |
| Gross margin | n/a | n/a | 55.7% | n/a |
| Operating margin | n/a | -449.9% | -65.2% | n/a |
| Net margin | n/a | -412.9% | -40.4% | n/a |
| Net income | -$299.62M | -$278.67M | -$103.27M | -$1.08B |
| EPS (Diluted) | -$4.66 | -$3.18 | -$1.41 | -$1.44 |
| Operating cash flow | -$241.10M | -$64.06M | $13.90M | -$322.93M |
| Free cash flow | -$241.73M | -$70.70M | $12.46M | -$323.59M |
| Cash & equivalents | $354.73M | $149.10M | $230.52M | $225.27M |
| Total assets | $734.73M | $738.36M | $726.16M | $751.18M |
| Total liabilities | $130.21M | $564.23M | $362.11M | $92.32M |
| Shareholders' equity | $604.52M | $174.13M | $364.05M | $658.86M |
| Return on year-end equity | -49.6% | -160.0% | -28.4% | -163.9% |
| Shares outstanding | n/a | 87.86M | n/a | 775.37M |
Revenue, most recent five fiscal years
| Fiscal year | Vera Therapeutics, Inc. | Kura Oncology, Inc. | Schrodinger, Inc. | Summit Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $67.48M Ended 2025-12-31 | $255.87M Ended 2025-12-31 | $0 Ended 2024-12-31 |
| 1 year earlier | n/a | $53.88M Ended 2024-12-31 | $207.54M Ended 2024-12-31 | $0 Ended 2023-12-31 |
| 2 years earlier | n/a | $0 Ended 2023-12-31 | $216.67M Ended 2023-12-31 | $705.0K Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $180.96M Ended 2022-12-31 | $1.81M Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $137.93M Ended 2021-12-31 | $860.0K Ended 2020-12-31 |